Vornorexant

Vornorexant

Clinical data
Other names	ORN-0829; TS-142
Routes of administration	By mouth
Drug class	Orexin antagonist
Pharmacokinetic data
Elimination half-life	1.3–3.3 hours
Identifiers
IUPAC name [(2S)-2-[[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]methyl]-1,3-oxazinan-3-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone
CAS Number	2265899-49-6
PubChem CID	137419776
ChemSpider	61751857
UNII	ZY54BP1CK3
Chemical and physical data
Formula	C23H22FN7O2
Molar mass	447.474 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=CC(=C(C=C1)N2N=CC=N2)C(=O)N3CCCO[C@H]3CN4C=CC(=N4)C5=NC=C(C=C5)F
InChI InChI=1S/C23H22FN7O2/c1-16-3-6-21(31-26-8-9-27-31)18(13-16)23(32)30-10-2-12-33-22(30)15-29-11-7-20(28-29)19-5-4-17(24)14-25-19/h3-9,11,13-14,22H,2,10,12,15H2,1H3/t22-/m0/s1 Key:AEZZJXJIJFSUEM-QFIPXVFZSA-N

Vornorexant, also known by its developmental code names ORN-0829 and TS-142, is an orexin antagonist medication which is under development for the treatment of insomnia and sleep apnea. It is a dual orexin OX₁ and OX₂ receptor antagonist (DORA). The medication is taken by mouth. As of June 2021, vornorexant is in phase 2 clinical trials for insomnia and phase 1 trials for sleep apnea. It is under development by Taisho Pharmaceutical.

Vornorexant has a time to peak of 2.5 hours and a relatively short elimination half-life of 1.3 to 3.3 hours. It was designed to have a short half-life and duration in order to reduce next-day side effects like somnolence.

See also

• Seltorexant – another investigational short-acting orexin receptor antagonist
• List of investigational sleep drugs § Orexin receptor antagonists

External links

• Vornorexant (ORN-0829, TS-142) - AdisInsight